|
Gender (%)/Chi-squared test
| | | | |
0.35
| | | | |
0.14
| | | | |
0.0016**
|
|
Male
|
41 (43.2)
|
66 (42.6)
|
75 (48.4)
|
51 (53.1)
| |
47 (58.0)
|
53 (55.8)
|
66 (69.5)
|
55 (67.9)
| |
76 (75.2)
|
102 (65.4)
|
131 (84.0)
|
70 (69.3)
| |
|
Female
|
54 (56.8)
|
89 (57.4)
|
80 (51.6)
|
45 (46.9)
| |
34 (42.0)
|
42 (44.2)
|
29 (30.5)
|
26 (32.1)
| |
25 (24.8)
|
54 (34.6)
|
25 (16.0)
|
31 (30.7)
| |
|
Median age (IQR)/ANOVA
|
66.5 (57.7–72.2)
|
69.4 (62.7–75.0)
|
63.3 (56.2–71.6)
|
65.3 (60.5–72.0)
|
< 0.0001****
|
56.7 (46.4–64.8)
|
56.3 (45.0–71.6)
|
56.1 (49.0–68.7)
|
60.0 (46.4–70.9)
|
0.71
|
60.77 (53.51–68.99)
|
61.11 (55.03–69.86)
|
60.85 (53.03–67.88)
|
61.72 (53.04–69.02)
|
0.72
|
|
Pathologic T (%)/Chi-squared test
| | | | |
0.16
| | | | |
0.068
| | | | |
0.018*
|
|
T0–2
|
86 (90.5)
|
139 (90.8)
|
129 (83.8)
|
81 (84.4)
| |
38 (58.5)
|
39 (52.0)
|
35 (45.5)
|
24 (36.4)
| |
37 (41.1)
|
64 (48.5)
|
41 (30.0)
|
40 (43.0)
| |
|
T3–4
|
9 (9.5)
|
14 (9.2)
|
25 (16.2)
|
15 (15.6)
| |
27 (41.5)
|
36 (48.0)
|
42 (54.5)
|
42 (63.6)
| |
53 (58.9)
|
68 (51.5)
|
96 (70.0)
|
53 (57.0)
| |
|
Pathologic N (%)/Chi-squared test
| | | | |
< 0.0001****
| | | | |
0.3
| | | | |
0.42
|
|
N0–1
|
81 (85.3)
|
139 (93.9)
|
115 (75.2)
|
83 (88.3)
| |
50 (68.5)
|
66 (77.6)
|
59 (68.6)
|
55 (78.6)
| |
40 (49.4)
|
71 (60.2)
|
77 (58.8)
|
51 (60.0)
| |
|
N2–3
|
14 (14.7)
|
9 (6.1)
|
38 (24.8)
|
11 (11.7)
| |
23 (31.5)
|
19 (22.4)
|
27 (31.4)
|
15 (21.4)
| |
41 (50.6)
|
47 (39.8)
|
54 (41.2)
|
34 (40.0)
| |
|
Pathologic M (%)/Fisher's test
| | | | |
0.3
| | | | |
0.27
| | | | |
0.16
|
|
M0
|
69 (94.5)
|
95 (96.0)
|
105 (92.1)
|
63 (88.7)
| |
70 (93.3)
|
86 (96.6)
|
87 (94.6)
|
64 (88.9)
| |
40 (100)
|
56 (100)
|
57 (100)
|
29 (96.7)
| |
|
M1
|
4 (5.5)
|
4 (4.0)
|
9 (7.9)
|
8 (11.3)
| |
5 (6.7)
|
3 (3.4)
|
5 (5.4)
|
8 (11.1)
| |
0
|
0
|
0
|
1 (3.3)
| |
|
Pathologic stage (%)/Chi-squared test
| | | | |
< 0.0001****
| | | | |
0.38
| | | | |
0.16
|
|
Stage I
|
47 (49.5)
|
106 (69.3)
|
64 (41.3)
|
54 (56.3)
| |
19 (25.7)
|
24 (28.9)
|
18 (19.8)
|
14 (19.4)
| |
2 (2.2)
|
11 (8.5)
|
5 (3.7)
|
9 (9.9)
| |
|
Stage II
|
28 (29.5)
|
31 (20.3)
|
43 (27.7)
|
19 (19.8)
| |
12 (16.2)
|
19 (22.9)
|
29 (31.9)
|
23 (31.9)
| |
13 (14.6)
|
28 (21.7)
|
17 (12.6)
|
15 (16.5)
| |
|
Stage III
|
16 (16.8)
|
11 (7.2)
|
39 (25.2)
|
14 (14.6)
| |
38 (51.4)
|
37 (44.6)
|
39 (42.9)
|
28 (38.9)
| |
18 (20.2)
|
20 (15.5)
|
24 (17.8)
|
17 (18.7)
| |
|
Stage IV
|
4 (4.2)
|
5 (3.3)
|
9 (5.8)
|
9 (9.4)
| |
5 (6.8)
|
3 (3.6)
|
5 (5.5)
|
7 (9.7)
| |
56 (62.9)
|
70 (54.3)
|
89 (65.9)
|
50 (54.9)
| |
|
Survival rate (%)/log-rank
| | | | |
< 0.0001****
| | | | |
< 0.0001****
| | | | |
0.39
|
|
3-year OS
|
60.7
|
78.4
|
45.5
|
69.2
| |
75
|
85.1
|
60.8
|
79.4
| |
56.2
|
65.6
|
52.7
|
54.4
| |
|
5-year OS
|
41.2
|
55
|
30.2
|
40.1
| |
65.1
|
78.4
|
43.2
|
63.3
| |
46.2
|
50.3
|
47
|
47.4
| |
